Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided an update on the clinical program for preladenant,
Mercks investigational adenosine A2A receptor antagonist for
the treatment of Parkinsons disease (PD). An initial review of data
from three separate Phase III trials did not provide evidence of
efficacy for preladenant compared with placebo.
Language:
English
Contact HTML:
MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more